A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Mutations in oncogenes often promote tumorigenesis by changing the conformation of the encoded proteins, thereby altering enzymatic activity. The PIK3CA oncogene, which encodes p110α, the catalytic subunit of phosphatidylinositol 3-kinase alpha (PI3Kα), is one of the two most frequently mutated oncogenes in human cancers. We report the structure of the most common mutant of p110α in complex with two interacting domains of its regulatory partner (p85α), both free and bound to an inhibitor (wortmannin). The N-terminal SH2 (nSH2) domain of p85α is shown to form a scaffold for the entire enzyme complex, strategically positioned to communicate extrinsic signals from phosphopeptides to three distinct regions of p110α. Moreover, we found that Arg-1047 points toward the cell membrane, perpendicular to the orientation of His-1047 in the WT enzyme. Surprisingly, two loops of the kinase domain that contact the cell membrane shift conformation in the oncogenic mutant. Biochemical assays revealed that the enzymatic activity of the p110α His1047Arg mutant is differentially regulated by lipid membrane composition. These structural and biochemical data suggest a previously undescribed mechanism for mutational activation of a kinase that involves perturbation of its interaction with the cellular membrane.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“A mutation observed in glioblastoma in the nSH2 domain, Gly376Arg, is part of this interface (25, 26).”
BackgroundSelf-citationThe phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · cited 1×
“Once activated by binding to the platelet-derived growth factor receptor (PDGFR) or other receptor kinases, the enzyme phosphorylates phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2, or PIP2] to generate phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane (12, 13).”
BackgroundErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 2×
“Successful drug developments based on this principle are exemplified by the EGFR kinase inhibitors gefitinib and erlotinib, both approved for clinical use (3, 4).”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Self-citationFukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
The PI3K‒PDK1 connection: more than just a road to PKB
Vanhaesebroeck, B., & Alessi, D. R. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460561 · Cited by 1,644
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., & Williams, R. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00089-4 · Cited by 1,197
Arcaro, A., & Wymann, M. P. (1993) · Biochemical Journal · doi:10.1042/bj2960297 · Cited by 1,140
Signaling by Distinct Classes of Phosphoinositide 3-Kinases
Vanhaesebroeck, B., & Waterfield, M. D. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4701 · Cited by 853
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C.-H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 560
Self-citation[10] Electron-density map interpretation
Jones, T. A., & Kjeldgaard, M. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)77012-5 · Cited by 505
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437
Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit
Miled, N., Yan, Y., Hon, W.-C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H. J., Backer, J. M., & Williams, R. L. (2007) · Science · doi:10.1126/science.1135394 · Cited by 410
Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 313
Kang, S., Denley, A., Vanhaesebroeck, B., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510772103 · Cited by 267
Regulation of the p85/p110α Phosphatidylinositol 3′-Kinase
Yu, J., Wjasow, C., & Backer, J. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30199 · Cited by 181
Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes
Nolte, R. T., Eck, M. J., Schlessinger, J., Shoelson, S. E., & Harrison, S. C. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0496-364 · Cited by 137
Catasús, L., Gallardo, A., Cuatrecasas, M., & Prat, J. (2007) · Modern Pathology · doi:10.1038/modpathol.3800992 · Cited by 133
Carson, J. D., Van Aller, G., Lehr, R., Sinnamon, R. H., Kirkpatrick, R. B., Auger, K. R., Dhanak, D., Copeland, R. A., Gontarek, R. R., Tummino, P. J., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070681 · Cited by 116
Oncogenic signaling of class I PI3K isoforms
Denley, A., Kang, S. G., Kärst, U., & Vogt, P. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210918 · Cited by 114
Al-Mulla, F., Milner-White, E. J., Going, J. J., & Birnie, G. D. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199903)187:4<433::aid-path273>3.0.co;2-e · Cited by 110
PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients
Lai, Y. L., Mau, B.-L., Cheng, W., Chen, H. M., Chiu, H., & Tzen, C. ‐. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9751-7 · Cited by 107
Structural comparisons of class I phosphoinositide 3-kinases
Amzel, L. M., Huang, C.-H., Mandelker, D., Lengauer, C., Gabelli, S. B., & Vogelstein, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2443 · Cited by 103
Self-citationThe Catalytic Subunit of Phosphoinositide 3-Kinase: Requirements for Oncogenicity
Aoki, M., Schetter, C., Himly, M., Batista, O., Chang, H. W., & Vogt, P. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.9.6267 · Cited by 87
Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas
Lerma, E., Catasús, L., Gallardo, A., Peiró, G., Alonso, C., Aranda, I., Barnadas, A., & Prat, J. (2008) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-008-0643-4 · Cited by 36
Cited by
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
“Increasing the positive surface charge of p110α might also be important for the His1047Arg hotspot mutatio”
BackgroundPhosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638
“Generally speaking, most PtdIns mono-phosphorylations (by the PI4Ks and Class III PI3K) occur in endomembranes, such as the endosomes and the Golgi/trans-Golgi network, whereas the phosphorylation of PtdIns4P to PtdIns(4,5)P2 by PIP 5-kinases and further to PtdIns(3,4,5)P3 by class I PI3Ks occurs primarily at the PM.”
BackgroundInfluentialPI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances
Lionta, E., Spyrou, G., Vassilatis, D., & Cournia, Z. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140929124445 · Cited by 1,165
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
Metadata
- Authors
- Mandelker, D., Gabelli, S. B., Schmidt-Kittler, O., Zhu, J., Cheong, I., Huang, C.-H., Kinzler, K. W., Vogelstein, B., & Amzel, L. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-10-06
- Volume
- 106
- Issue
- 40
- Pages
- 16996-17001
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2090038231
- Cited by
- 293
- References
- 31
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.